LUCD
Lucid Diagnostics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Lucid Diagnostics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, a esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, a esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Lucid Diagnostics Inc.
0.41
| Manager | Value | % base | |
|---|---|---|---|
| Alyeska Investment | $9.5M | 14.40% | new |
| BlackRockindex-like | $9.0M | 13.61% | +80.52% |
| Vanguardindex-like | $7.0M | 10.66% | +57.80% |
| Two Seas Capital | $6.4M | 9.75% | +100.00% |
| Masters | $4.3M | 6.50% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Alyeska Investment | $9.5M | 14.40% | new |
| BlackRockindex-like | $9.0M | 13.61% | +80.52% |
| Vanguardindex-like | $7.0M | 10.66% | +57.80% |
| Two Seas Capital | $6.4M | 9.75% | +100.00% |
| Masters | $4.3M | 6.50% | 0.00% |
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Lucid Diagnostics Inc.'s 3 closest co-movers, none share that code.
Closest co-movers · 499d
ACHRArcher Aviation×0.34r 0.27UPSTUpstart Holdings×0.32r 0.25SIShoulder Innovations×0.30r 0.25Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Lucid Diagnostics Inc.'s 3 closest co-movers, none share that code.
Bull3
Bear1
Linked news
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.